<DOC>
	<DOCNO>NCT02281682</DOCNO>
	<brief_summary>A multi-centre randomise control single blind clinical phase IV trial aim determine effective treatment term lesion reduction , cost patient satisfaction treatment actinic keratosis ( AK ) , compare topical treatment photodynamic therapy ( PDT ) , 5 % 5-fluorouracil ( 5-FU ) cream , 5 % Imiquimod ( IMI ) cream ingenol mebutate ( IM ) gel .</brief_summary>
	<brief_title>IM Versus 5-FU Versus IMI Versus MAL-PDT Treatment Actinic Keratosis</brief_title>
	<detailed_description>Skin cancer common cancer Caucasians therefore major public health issue . Its incidence increase rapidly . Actinic keratosis ( AK ) prevalent precancerous chronic skin condition . It transform squamous cell carcinoma ( SCC ) . AK 's generally arise skin area diffuse precancerous damage , phenomenon call field cancerization . Because precancerous character , advise treat AK herewith prevent development SCC . The frequently use field-directed treatment Netherlands photodynamic therapy ( PDT ) , topical 5 % f-fluorouracil ( 5 % 5-FU ) topical 5 % Imiquimod ( 5 % IMI ) . Lately another topical product approve Dutch healthcare insurance : Ingenol mebutate ( IM ) . Up date , treatment patient receive , rely evidence-based-medicine , generally preference physician . Current national international guideline state clear recommendation best choice therapy . The aim study determine treatment effective treatment term lesion reduction , cost patient satisfaction compare topical treatment photodynamic therapy ( PDT ) , 5 % 5-fluorouracil ( 5-FU ) cream , 5 % Imiquimod ( IMI ) cream ingenol mebutate ( IM ) gel , treatment actinic keratosis ( AK ) .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<mesh_term>Methyl 5-aminolevulinate</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Patients older 18 year Fitzpatrick skintype IIV Clinically confirm diagnosis AK One joint area minimal 25 cm2 maximal 100 cm2 AK Minimum 5 AK lesion AK Olsen grade IIII Location : head/neck area Received kind treatment AK past 3 month ( non ) melanoma skin cancer target area Immunocompromised status Use systemic retinoid past 3 month Use immunosuppressant drug past 3 month / time treatment ( oral glucocorticoid , cytostatic , antibody , drug acting immunophilins , interferon , opioids , Tumor Necrosis Factor ( TNF ) binding protein , mycofenolate mofetil ( MMF ) , biologic agent ) . inhalation corticosteroid / nasal corticosteroid permit . Porphyria Not able give inform consent Allergy study drug peanut/nut/soy product Pregnant breastfeed woman Female child bear potential use contraceptive measure , till 3 month posttreatment Genetic skin cancer disorder Not understand Dutch language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Keratosis , Actinic</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>cost-effectiveness</keyword>
	<keyword>economic evaluation</keyword>
	<keyword>imiquimod</keyword>
	<keyword>photodynamic therapy</keyword>
	<keyword>topical fluorouracil</keyword>
	<keyword>ingenol mebutate</keyword>
</DOC>